María Mercedes
Garayoa Berrueta
Publicaciones en las que colabora con María Mercedes Garayoa Berrueta (14)
2015
-
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone
Leukemia, Vol. 29, Núm. 3, pp. 705-714
2014
2013
-
RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications
Investigational New Drugs, Vol. 31, Núm. 1, pp. 200-205
-
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects
Leukemia, Vol. 27, Núm. 2, pp. 430-440
2012
-
CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype
Haematologica, Vol. 97, Núm. 7, pp. 1110-1114
-
Dasatinib as a bone-modifying agent: Anabolic and anti-resorptive effects
PLoS ONE, Vol. 7, Núm. 4
2011
-
Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response
Haematologica, Vol. 96, Núm. 5, pp. 687-695
2010
-
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma
Haematologica, Vol. 95, Núm. 5, pp. 794-803
2009
-
Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors
Leukemia, Vol. 23, Núm. 8, pp. 1515-1527
-
The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair
Leukemia, Vol. 23, Núm. 12, pp. 2265-2274
-
Zalypsis: A novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks
Blood, Vol. 113, Núm. 16, pp. 3781-3791
2008
-
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo
Cancer Research, Vol. 68, Núm. 13, pp. 5216-5225
-
The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype
Haematologica, Vol. 93, Núm. 1, pp. 57-66
-
The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells
British Journal of Haematology, Vol. 141, Núm. 4, pp. 470-482